XenoGesis Ltd. is a laboratory-based contract research organisation (CRO) specialised in preclinical drug metabolism & pharmacokinetics (DMPK), quantitative bioanalysis and expert interpretation. 
View this email in your browser


Welcome to the latest newsletter from XenoGesis. As ever, there is a lot to report following another busy few months. Not least, since our last newsletter we have welcomed three new starters, as well as an Erasmus placement student who is with us until the Spring. Furthermore, our growth has seen us expand into the US with the appointment of Sabrina Mogle - more on that story later in the newsletter. 

In September we launched our new website which aims to give greater detail about the services available at XenoGesis. Our new 'At A Glance' overview clearly outlines the core services we now offer. We have also launched our Packaged Services designed to help make better informed decisions in your drug discovery cascade in an easy, one-stop approach.

Last month we were out and about attending BioSpain, BOS London and the Biohomecoming event in Leicester. And looking ahead we will be attending the European Bioanalytical Forum Open Symposium in Barcelona, LATi 2016 Showcase and the ISSX Workshop - 'Translating Data to Human Clearance and Pharmacokinetics' in Boston.

As we move through Autumn, we will be celebrating our 5th birthday, and will have further exciting news to share about our new Bioanalysis and Metabolic Identification Suite that will add to our capabilities and enable us to offer an even more effective service to our clients.

Warm regards
Richard Weaver

Team news

Expansion into the US with the appointment of Sabrina Mogle

XenoGesis has appointed Sabrina Mogle as a consultant to spearhead US business development strategy, industry awareness and growth efforts.

Sabrina has extensive experience in business and corporate development and strategy having spent her entire career in the biotechnology and pharmaceutical industry.

Read more 


XenoGesis increases capabilities, adding CYP induction and gene expression assay services to its portfolio 

XenoGesis has invested in a state of the art Agilent AriaMx Real-time PCR system, further expanding its quantitative PCR capabilities and adding CYP induction assays to its portfolio of services.

The Agilent AriaMx Real-time PCR is a fully integrated quantitative PCR amplification, detection and data analysis system and has a 96-well capacity. The machine enables any gene expression assays to be carried out which will expand XenoGesis’ range of assays beyond DMPK to now include pharmacology services.

Read more
Partner news

An integrated bio-pharmaceutics approach for effective drug development

In September, XenoGesis teamed up with Juniper Pharma Services to deliver a webinar that demonstrated and explained how our joint, consultative approach to drug development can help pharma companies take their compound through to clinic in a seamless, rapid and cost effective way. If you didn't get the chance to listen to the webinar, it is still available online here

Read more about our partnership with Juniper Pharma Services
Copyright © 2016 XenoGesis Ltd, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

Email Marketing Powered by Mailchimp